JP2022512965A5 - - Google Patents

Info

Publication number
JP2022512965A5
JP2022512965A5 JP2021525039A JP2021525039A JP2022512965A5 JP 2022512965 A5 JP2022512965 A5 JP 2022512965A5 JP 2021525039 A JP2021525039 A JP 2021525039A JP 2021525039 A JP2021525039 A JP 2021525039A JP 2022512965 A5 JP2022512965 A5 JP 2022512965A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
absent
methacrylate
linking group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021525039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512965A (ja
JP7588855B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059711 external-priority patent/WO2020093061A1/en
Publication of JP2022512965A publication Critical patent/JP2022512965A/ja
Publication of JP2022512965A5 publication Critical patent/JP2022512965A5/ja
Priority to JP2024158746A priority Critical patent/JP2024175018A/ja
Application granted granted Critical
Publication of JP7588855B2 publication Critical patent/JP7588855B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021525039A 2018-11-02 2019-11-04 治療方法 Active JP7588855B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024158746A JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755196P 2018-11-02 2018-11-02
US62/755,196 2018-11-02
PCT/US2019/059711 WO2020093061A1 (en) 2018-11-02 2019-11-04 Therapeutic methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024158746A Division JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Publications (3)

Publication Number Publication Date
JP2022512965A JP2022512965A (ja) 2022-02-07
JP2022512965A5 true JP2022512965A5 (https=) 2022-11-07
JP7588855B2 JP7588855B2 (ja) 2024-11-25

Family

ID=70463345

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525039A Active JP7588855B2 (ja) 2018-11-02 2019-11-04 治療方法
JP2024158746A Pending JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024158746A Pending JP2024175018A (ja) 2018-11-02 2024-09-13 治療方法

Country Status (14)

Country Link
US (1) US20220031847A1 (https=)
EP (1) EP3873530A4 (https=)
JP (2) JP7588855B2 (https=)
KR (1) KR20210120988A (https=)
CN (1) CN113365662A (https=)
AU (1) AU2019370563B2 (https=)
BR (1) BR112021008449A2 (https=)
CA (1) CA3118142A1 (https=)
EA (1) EA202191210A1 (https=)
IL (1) IL282794B2 (https=)
MX (1) MX2021005130A (https=)
NZ (1) NZ776256A (https=)
SG (1) SG11202104461XA (https=)
WO (1) WO2020093061A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions
JP2022506517A (ja) * 2018-11-02 2022-01-17 アルブータス・バイオファーマー・コーポレイション 標的指向化二価結合体
EP4007811A2 (en) * 2019-08-01 2022-06-08 Alnylam Pharmaceuticals, Inc. Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof
AU2020398708A1 (en) * 2019-12-06 2022-07-14 Genevant Sciences Gmbh Conjugates and methods for treating liver fibrosis
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
CN114846051A (zh) * 2019-12-20 2022-08-02 阿布特斯生物制药公司 合成方法和中间体
EP4228658A4 (en) 2020-10-14 2025-02-19 George Mason Research Foundation, Inc. IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
US11649260B2 (en) 2021-06-18 2023-05-16 Hongene Biotech Corporation Functionalized N-acetylgalactosamine nucleosides
EP4396193A4 (en) 2021-08-30 2025-07-02 Hongene Biotech Corp FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGUES
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023097186A1 (en) * 2021-11-24 2023-06-01 The Regents Of The University Of California Compositions and methods for enhancing visual function
JP2024546585A (ja) 2021-12-15 2024-12-26 ホンジーン バイオテック コーポレイション 官能基化n-アセチルガラクトサミンアナログ
CN118591552A (zh) * 2022-01-30 2024-09-03 成都凌泰氪生物技术有限公司 一种配体、其制备方法及应用
AU2023238507A1 (en) * 2022-03-25 2024-10-31 Hansoh Bio Llc Bicyclic heterocycles and their ligands for targeted delivery of therapeutic agents
US20250215042A1 (en) * 2022-04-01 2025-07-03 Genevant Sciences Gmbh Mannose-targeted compositions
WO2024057190A2 (en) * 2022-09-12 2024-03-21 Genevant Sciences Gmbh Targeted compositions
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
CN118993970B (zh) * 2023-05-17 2025-12-23 苏州富士莱医药股份有限公司 一种l96侧链化合物的制备方法
CN119219716A (zh) * 2023-06-30 2024-12-31 上海维申医药有限公司 新型GalNAc的靶向递送片段及其制备和应用
GB202311334D0 (en) * 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
IL326647A (en) 2023-09-01 2026-04-01 Novoarc Gmbh Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
CN117624266A (zh) * 2023-10-19 2024-03-01 弘亮(上海)生物医药科技有限公司 一种肝靶向化合物及其寡核苷酸缀合物、偶联方法与应用
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
CN121045314B (zh) * 2025-10-31 2026-04-14 南昌市第一医院 一种靶向降解hmgb1的化合物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285853B1 (en) * 2008-05-13 2013-02-27 University of Washington Micellic assemblies
US9415113B2 (en) * 2009-11-18 2016-08-16 University Of Washington Targeting monomers and polymers having targeting blocks
AU2014296278C1 (en) * 2013-07-30 2023-02-02 Genevant Sciences Gmbh Block copolymers and their conjugates or complexes with oligonucleotides
JP2018509387A (ja) * 2015-01-21 2018-04-05 フェーズアールエックス インコーポレイテッド 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム
CA3020585A1 (en) * 2016-04-11 2017-10-19 Arbutus Biopharma Corporation Targeted nucleic acid conjugate compositions
EP3562510A4 (en) * 2016-12-30 2021-01-06 Genevant Sciences GmbH BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES
MX2019012280A (es) * 2017-04-11 2020-01-23 Arbutus Biopharma Corp Composiciones dirigidas.

Similar Documents

Publication Publication Date Title
JP2022512965A5 (https=)
JP2024175018A5 (https=)
JP2021075543A (ja) アルギナーゼ活性を阻害する組成物及び方法
AU2023248123B2 (en) Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments
JP2013523896A5 (https=)
CA2745302A1 (en) Zwitterionic polymers with therapeutic moieties
JP7764041B2 (ja) 脳腫瘍における改善された血液脳関門浸透性及び滞留性を備えた、スケーラブルなチロインテグリンアンタゴニストの組成物
JP2011168799A (ja) 化学的に異なる末端基を含むポリ(エチレングリコール)
KR20230124980A (ko) 쯔비터이온성 지질 나노입자 조성물 및 사용 방법
RU2012144554A (ru) КОНЪЮГИРОВАННЫЙ ФАКТОР СВЕРТЫВАНИЯ КРОВИ VIIa
JPWO2013073697A1 (ja) フェニルボロン酸基が導入されたブロックコポリマーおよびその使用
AU2014266254B2 (en) Polymeric micelle pharmaceutical composition
JP2014519507A5 (https=)
RU2013156939A (ru) Способ лечения лихорадки денге
TW201143797A (en) Easily collapsible polymer micelle composition
BR112021010043A2 (pt) Níveis de fármaco locais sustentados para agonistas imunes inatos
EP3710061A1 (fr) Prodrogues polymères et leur administration sous-cutanee et/ou intramusculaire
JP7376694B2 (ja) 再生可能資源に由来するポリマーおよび組成物
WO2022168967A1 (ja) 新規なコポリマー
WO2011049042A1 (ja) 腹腔内投与用の抗がん剤含有ブロック共重合体、ミセル調製物及びそれを有効成分とする癌治療薬
JP6837962B2 (ja) 活性薬剤の送達のための両親媒性ブロックコポリマー
JP2008229213A (ja) 生体適合性接着剤組成物
CN109908356B (zh) 负载抗肿瘤药物的氰基丙烯酸酯材料
US20220387596A1 (en) Biodegradable hydrogel and methods for use thereof
JP2011012042A (ja) 核酸徐放担体